All Articles

How Scotland’s regional data centres prioritize American cloud giants over public healthcare infrastructure.

Ireland's structured approach to scaling digital pathways exposes the evidential gaps in England's own virtual ward expansion.

NHS England's retreat on patient data access exposes a gap between the ambitions of centralised health data and the unglamorous work of governing who gets to look at it.

How a near-affordable oral GLP-1, private-only until at least November, is likely to widen the gap between what patients can buy and what their local NHS will fund.

New community hubs and emergency departments mark an early domestic policy test for Yvette Cooper, while Somerset ICB's separate tender points to the smaller-scale procurement decisions now running alongside the national rollout.

The legal fight over sleep accuracy could have consequences far beyond consumers, including NHS observational studies, digital biomarkers and the future of wearable-led research.

As Experian promises to keep financial data isolated in AI tools, the NHS's recent privacy slip-ups show why tech architecture promises are getting harder for the public to trust.

TidalSense's £16 million raise lands the same week NHS England begins scoping the commercial architecture for AI-led diagnostics, and the gap between funding and delivery is where the real story sits.

Whistleblower claims at one of England's largest trusts suggest that regulatory intervention can coexist with a workplace where staff no longer trust the reporting system meant to protect patients.

Renewed theatre strikes at an enforcement-flagged trust raise questions about managerial consistency rather than clinical safety.

Google's wrist-worn health insights arrive as Whitehall's own prevention strategy struggles to move beyond aspiration.

Why the trust issue that is still impeding NHS data reform is highlighted by a £16.14 million cybersecurity raise.

Employment tribunal finds former director's sacking followed a deeply flawed investigation, with the trust's ex-chief executive found to have misled the process, as the wider Humber group remains under intensive national oversight.

Authorisation of Eli Lilly's Foundayo marks a European regulatory first, but the drug's path onto NHS formularies now depends on how quickly NICE can complete its evaluation.

As dozens of trusts weigh closure against staffing collapse, the NHS is being forced into a choice it has spent decades avoiding: proximity or survival.

As Advice and Guidance becomes contractually mandatory across general practice, the gap between its stated purpose and its lived effect is exposing how liability, not capacity, has become the NHS's quietest crisis.

Investigators warn that gaps in oversight of the Advice and Guidance policy left patients falling between primary and secondary care, as regulators separately press NHS England on the safety of its expansion.

Eleven cases in Barry since December have forced a five-day vaccination drive at a district hospital, and exposed how little the UK's immunisation architecture has adapted to a disease it has chosen to manage only after the fact.

HMRC's £78.2m Atos deal exposes a widening gap between how government departments spread technology risk and how the health service concentrates it.

Allergy Therapeutics' turnaround, and the case it makes for backing homegrown immunotherapy through a difficult financing climate.